Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
3(50%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
5
83%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(3)

Detailed Status

Terminated3
Completed3

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

terminated350%
completed350%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

NCT02381535
completedphase_1

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02503709
terminatedphase_1

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02097225
completedphase_1

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

NCT02898207
terminatedphase_1

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

NCT02474173
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02381535Phase 1

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

Completed
NCT02503709Phase 1

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Completed
NCT02097225Phase 1

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Terminated
NCT02898207Phase 1

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Completed
NCT02474173Phase 1

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Terminated
NCT02572453Phase 2

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6